francesco lanza- uo ematologia- ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3%...
TRANSCRIPT
![Page 1: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/1.jpg)
Discutendo di trapianto di cellule staminali allogeniche
Francesco Lanza- UO Ematologia- Ravenna
![Page 2: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/2.jpg)
HSCT ACTIVITY IN EUROPE : EBMT REGISTRY
21 586 (57%)
16 030 (43%)
EBMT INDICATION MANUSCRIPT : to be published in May 2017
![Page 3: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/3.jpg)
![Page 4: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/4.jpg)
CELLULAR THERAPY ACTIVITY IN EUROPE
![Page 5: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/5.jpg)
ALLO-‐ SCT
![Page 6: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/6.jpg)
AUTO-‐SCT
5% ST
![Page 7: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/7.jpg)
![Page 8: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/8.jpg)
![Page 9: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/9.jpg)
![Page 10: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/10.jpg)
![Page 11: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/11.jpg)
![Page 12: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/12.jpg)
![Page 13: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/13.jpg)
![Page 14: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/14.jpg)
![Page 15: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/15.jpg)
![Page 16: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/16.jpg)
![Page 17: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/17.jpg)
![Page 18: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/18.jpg)
![Page 19: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/19.jpg)
HAPLO-‐BMT
Child
![Page 20: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/20.jpg)
HAPLO-‐BMT
![Page 21: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/21.jpg)
HAPLO-‐BMT
![Page 22: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/22.jpg)
![Page 23: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/23.jpg)
![Page 24: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/24.jpg)
24
EBMT Registry-Solid Tumour Working Party March 2017
Solid tumour Registry 55 641
Patients 40 663 Aduts/Paediatric (%) 59/ 41
Male/Female (%) 48 / 52 Auto / Allo (%) 97 / 3
Nb of HSCT Auto (n=53 865) Allo (n=1 731) First HSCT 39 284 1162
Second HSCT 9 781 430 Third HSCT 3 440 76
Fourth HSCT 623 27 > Fifth HSCT 190 9
Median follow up (yr<2016) 2, (<1-35) 1,8 (<1-31)
![Page 25: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/25.jpg)
25
Solid Tumour Working Party Allo / Year 1990-2016* (n=1660)- EBMT Registry February 2017
1990-2016
![Page 26: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/26.jpg)
26
Solid Tumour Working Party Autologous– Adults/ paediatric-‐ 1990/2016
EBMT Registry -‐ February 2017*
1990-2016
![Page 27: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/27.jpg)
27
Solid Tumour Working Party Autologous / main indicaWons-‐ EBMT Registry – February 2017
1990-2016
![Page 28: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/28.jpg)
28
Solid Tumour Working Party Nr of auto performed for GCT/Year in adult paWents
1990-‐2016 (n= 10 274)
Germ Cell Tumours
![Page 29: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/29.jpg)
![Page 30: Francesco Lanza- UO Ematologia- Ravenna · 24 304 (67%; 20% allogeneic), solid tumors 1516 (4%; 3% allogeneic) and non-malignant disorders 2208 (6%; 90% allogeneic). Remarkable is](https://reader034.vdocuments.mx/reader034/viewer/2022050113/5f49f78a0b576571d57ae936/html5/thumbnails/30.jpg)